Selected article for: "affinity cell and SARS cov"
Author: Beasley, Matthew D.; Aracic, Sanja; Gracey, Fiona M.; Kannan, Ruban; Masarati, Avisa; Premaratne, S. R.; Udawela, Madhara; Wood, Rebecca E.; Jabar, Shereen; Church, Nicole L.; Le, Thien-Kim; Makris, Dahna; McColl, Bradley K.; Kiefel, Ben R.
Title: Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries
  • Cord-id: qwfc01no
  • Document date: 2020_7_28
    • ID: qwfc01no
    Snippet: Antibodies with high affinity against the receptor binding domain (RBD) of the SARS-CoV-2 S1 ectodomain were identified from screens using the Retained Display™ (ReD) platform employing a 1 × 1011 clone single-chain antibody (scFv) library. Numerous unique scFv clones capable of inhibiting binding of the viral S1 ectodomain to the ACE2 receptor in vitro were characterized. To maximize avidity, selected clones were reformatted as bivalent diabodies and monoclonal antibodies (mAb). The highest
    Document: Antibodies with high affinity against the receptor binding domain (RBD) of the SARS-CoV-2 S1 ectodomain were identified from screens using the Retained Display™ (ReD) platform employing a 1 × 1011 clone single-chain antibody (scFv) library. Numerous unique scFv clones capable of inhibiting binding of the viral S1 ectodomain to the ACE2 receptor in vitro were characterized. To maximize avidity, selected clones were reformatted as bivalent diabodies and monoclonal antibodies (mAb). The highest affinity mAb completely neutralized live SARS-CoV-2 virus in cell culture for four days at a concentration of 6.7 nM, suggesting potential therapeutic and/or prophylactic use. Furthermore, scFvs were identified that greatly increased the interaction of the viral S1 trimer with the ACE2 receptor, with potential implications for vaccine development.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and live sars infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and local epidemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • acute respiratory syndrome and long term efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and low infectivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and mabs neutralizing monoclonal antibody: 1
    • acute respiratory syndrome and mabs potent: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • ade antibody dependent enhancement and low infectivity: 1